Oppenheimer set a $82.00 price target on Global Blood Therapeutics (NASDAQ:GBT) in a research report report published on Monday. The firm currently has a buy rating on the stock.
GBT has been the subject of a number of other research reports. Cantor Fitzgerald set a $96.00 target price on Global Blood Therapeutics and gave the stock a buy rating in a research report on Tuesday, October 2nd. BidaskClub downgraded Global Blood Therapeutics from a hold rating to a sell rating in a research report on Wednesday, September 19th. Zacks Investment Research downgraded Global Blood Therapeutics from a buy rating to a hold rating in a research report on Thursday, October 4th. HC Wainwright restated a buy rating and issued a $150.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday, November 28th. Finally, ValuEngine downgraded Global Blood Therapeutics from a strong-buy rating to a buy rating in a research report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $83.20.
NASDAQ:GBT opened at $46.67 on Monday. The company has a market capitalization of $2.37 billion, a P/E ratio of -16.91 and a beta of 3.65. Global Blood Therapeutics has a 1-year low of $30.15 and a 1-year high of $68.05.
Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Tuesday, November 6th. The company reported ($0.83) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.02. During the same period in the prior year, the company posted ($0.66) earnings per share. On average, analysts expect that Global Blood Therapeutics will post -3.36 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in GBT. Focused Wealth Management Inc bought a new stake in Global Blood Therapeutics in the third quarter valued at approximately $104,000. PNC Financial Services Group Inc. lifted its position in Global Blood Therapeutics by 740.3% in the third quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock valued at $165,000 after purchasing an additional 3,835 shares during the last quarter. Rehmann Capital Advisory Group bought a new stake in Global Blood Therapeutics in the third quarter valued at approximately $165,000. Tiverton Asset Management LLC bought a new stake in Global Blood Therapeutics in the second quarter valued at approximately $166,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in Global Blood Therapeutics in the second quarter valued at approximately $203,000.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.